DK0943328T3 - Kombinationsterapi til profylakse og/eller behandling af godartet prostatahyperplasi - Google Patents

Kombinationsterapi til profylakse og/eller behandling af godartet prostatahyperplasi

Info

Publication number
DK0943328T3
DK0943328T3 DK99106510T DK99106510T DK0943328T3 DK 0943328 T3 DK0943328 T3 DK 0943328T3 DK 99106510 T DK99106510 T DK 99106510T DK 99106510 T DK99106510 T DK 99106510T DK 0943328 T3 DK0943328 T3 DK 0943328T3
Authority
DK
Denmark
Prior art keywords
treatment
benign prostatic
prostatic hyperplasia
prophylaxis
combination therapy
Prior art date
Application number
DK99106510T
Other languages
English (en)
Inventor
Fernand Labrie
Original Assignee
Endorech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorech Inc filed Critical Endorech Inc
Application granted granted Critical
Publication of DK0943328T3 publication Critical patent/DK0943328T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Fertilizers (AREA)
DK99106510T 1989-07-07 1990-07-05 Kombinationsterapi til profylakse og/eller behandling af godartet prostatahyperplasi DK0943328T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37670089A 1989-07-07 1989-07-07
EP90909598A EP0480950B1 (en) 1989-07-07 1990-07-05 Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
EP98104849A EP0857487A3 (en) 1989-07-07 1990-07-05 Combinations for prophylaxsis and/or treatment of benign prostatic hyperplasia containing a 17 beta-hydroxy steroid dehydrogenase (17bHSD) inhibitor and at least one further active ingredient

Publications (1)

Publication Number Publication Date
DK0943328T3 true DK0943328T3 (da) 2004-10-18

Family

ID=23486098

Family Applications (2)

Application Number Title Priority Date Filing Date
DK90909598T DK0480950T3 (da) 1989-07-07 1990-07-05 Kombinationsterapi til profylakse for og/eller behandling af godartet prostatahypertrofi
DK99106510T DK0943328T3 (da) 1989-07-07 1990-07-05 Kombinationsterapi til profylakse og/eller behandling af godartet prostatahyperplasi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK90909598T DK0480950T3 (da) 1989-07-07 1990-07-05 Kombinationsterapi til profylakse for og/eller behandling af godartet prostatahypertrofi

Country Status (17)

Country Link
US (1) US5817649A (da)
EP (3) EP0857487A3 (da)
JP (2) JP3332377B2 (da)
KR (1) KR920703063A (da)
AT (2) ATE269066T1 (da)
AU (2) AU643445B2 (da)
CA (1) CA2062973C (da)
DE (2) DE69034148T2 (da)
DK (2) DK0480950T3 (da)
ES (2) ES2133270T3 (da)
HU (1) HU223662B1 (da)
IE (2) IE990530A1 (da)
IL (1) IL94990A (da)
MY (1) MY106484A (da)
NZ (1) NZ234414A (da)
WO (1) WO1991000731A1 (da)
ZA (1) ZA905312B (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204337A (en) * 1988-10-31 1993-04-20 Endorecherche Inc. Estrogen nucleus derivatives for use in inhibition of sex steroid activity
DK0595796T3 (da) * 1989-07-07 2003-05-05 Endorech Inc Fremgangsmåde til behandling af androgen-relaterede sygdomme
IL101245A0 (en) * 1991-03-20 1992-11-15 Merck & Co Inc Pharmaceutical compositions for the treatment of prostatic cancer
WO1992018132A1 (en) * 1991-04-17 1992-10-29 Merck & Co., Inc. Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
US5175155A (en) * 1991-10-07 1992-12-29 Sterling Winthrop Inc. Win 49596-finasteride method of use and compositions
GB9506678D0 (en) * 1995-03-31 1995-05-24 Glaxo Inc Substituted 6-azacholesten-3-ones
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
MXPA00008868A (es) 1998-03-11 2003-04-25 Endorech Inc Inhibidores de dihidrogenasa de 17 -hidroxiesteroide y metodos para su uso.
EP1321146A3 (en) * 1998-03-11 2004-06-02 Endorecherche Inc. Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use
DE19825591A1 (de) * 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata
US6268377B1 (en) * 1998-09-28 2001-07-31 Merck & Co., Inc. Method for treating androgen-related conditions
US8278291B1 (en) 1999-08-13 2012-10-02 Curadis Gmbh Treatment of wrinkles and strias with 4-hydroxyandrostenedione or a derivative thereof
US6200573B1 (en) 1999-12-03 2001-03-13 Starcor Pharmaceuticals, Inc. Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7001911B2 (en) 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
HUP0303172A3 (en) 2000-06-28 2006-05-29 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification, desing and use
AU2001267904A1 (en) * 2000-06-30 2002-01-14 Chugai Seiyaku Kabushiki Kaisha Novel antiandrogenic agent
EP1854798A3 (en) 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US6953679B2 (en) 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
WO2002089802A2 (en) 2001-05-08 2002-11-14 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
AU2002322493A1 (en) * 2001-07-10 2003-01-29 Ams Research Corporation Surgical kit for treating prostate tissue
MY141661A (en) 2001-09-06 2010-05-31 Schering Corp 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
ES2347643T3 (es) 2001-10-17 2010-11-03 Schering Corporation Piperin- y piperazinacetamidas como inhibidores de 17beta hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades dependientes de androgenos.
US7087636B2 (en) 2001-12-19 2006-08-08 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
ES2345146T3 (es) 2002-11-18 2010-09-16 Schering Corporation Inhibidores de 17beta-hidroxiesteroides deshidrogenasa de tipo 3 para el tratamiento de enfermedades dependientes de androgenos.
AU2003293555A1 (en) 2002-12-17 2004-07-29 Schering Corporation 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
US20060258628A1 (en) * 2004-07-20 2006-11-16 Steiner Mitchell S Compositions comprising 5-alpha reductase inhibitors, and SARMs and methods of use thereof
CN106038572A (zh) 2004-10-20 2016-10-26 恩多研究公司 性甾体前体单独或与选择性雌激素受体调节剂联合用于预防和治疗绝经后女性的性功能障碍
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
US12290277B2 (en) 2007-01-02 2025-05-06 Aquabeam, Llc Tissue resection with pressure sensing
US9232959B2 (en) 2007-01-02 2016-01-12 Aquabeam, Llc Multi fluid tissue resection methods and devices
JP5369336B2 (ja) * 2007-01-02 2013-12-18 アクアビーム エルエルシー 前立腺の疾患を治療するための侵襲性が最小である方法及びデバイス
US9284345B2 (en) * 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
GB0708376D0 (en) 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
GB0722779D0 (en) 2007-11-20 2008-01-02 Sterix Ltd Compound
EP3622910B1 (en) 2008-03-06 2024-07-10 AquaBeam LLC Tissue ablation and cautery with optical energy carried in fluid stream
WO2014127242A2 (en) 2013-02-14 2014-08-21 Procept Biorobotics Corporation Aquablation aquabeam eye surgery methods and apparatus
WO2013130895A1 (en) 2012-02-29 2013-09-06 Aquabeam, Llc Automated image-guided tissue resection and treatment
US9848904B2 (en) 2009-03-06 2017-12-26 Procept Biorobotics Corporation Tissue resection and treatment with shedding pulses
MX2014009322A (es) * 2012-02-29 2014-11-10 Repros Therapeutics Inc Terapia de combinacion para el tratamiento de la deficiencia androgenica.
JP6461971B2 (ja) 2013-09-06 2019-01-30 プロセプト バイオロボティクス コーポレイション 飛散パルスを用いた組織切除および処置
CN106572864B (zh) 2014-06-30 2020-06-09 普罗赛普特生物机器人公司 流体射流组织切除和寒凝装置
JP2017532095A (ja) 2014-09-05 2017-11-02 プロセプト バイオロボティクス コーポレイション 標的器官画像の処理マッピングと一体化された医師制御組織切除

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329364A (en) * 1974-09-11 1982-05-11 Schering Corporation Antiandrogenic agents and methods for the treatment of androgen dependent disease states
US4039669A (en) * 1975-08-01 1977-08-02 Sterling Drug Inc. Composition for topical application and use thereof
US4087461A (en) * 1976-02-26 1978-05-02 The Johns Hopkins University Anti-androgenic steroids
DE2817157A1 (de) * 1978-04-17 1979-10-25 Schering Ag Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie
US4235893A (en) * 1978-05-08 1980-11-25 Brodie Angela M Ester derivatives of 4-hydroxy-4-androstene-3,17-dione and a method for inhibiting estrogen biosynthesis
FR2465486A1 (fr) * 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
US4474813A (en) * 1980-10-24 1984-10-02 Schering Corporation Pharmaceutical preparations comprising flutamide
DE3121153A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie"
DE3121152A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie"
US4347363A (en) * 1981-09-17 1982-08-31 Sterling Drug Inc. Process for preparing 1,2-dihydro-6-methyl-2-oxo-5-(pyridinyl)nicotinonitriles
DE3339295A1 (de) * 1982-11-15 1984-05-17 Schering AG, 1000 Berlin und 4709 Bergkamen 4-hydroxy- und 4-acyloxy-4-androsten-3,17-dione zur verwendung bei der prophylaxe und therapie der prostatahyperplasie und diese enthaltende mittel fuer derartige verwendung
AU565915B2 (en) * 1982-12-31 1987-10-01 Mortimer, C.H. Pharmaceutical composition of antibiotic and anti- androgen
DE3323321A1 (de) * 1983-06-24 1985-01-03 Schering AG, 1000 Berlin und 4709 Bergkamen Prophylaxe und therapie von koronaren herzkrankheiten durch senkung des oestrogenspiegels
DE3486090T2 (de) * 1983-12-12 1993-08-05 Kaszynski Edwin G Haarwuchsmodifikation.
US5053403A (en) * 1984-05-11 1991-10-01 Norman Orentreich Methods for treatment of male-pattern baldness
US4684635A (en) * 1984-05-11 1987-08-04 Norman Orentreich Compositions and methods for inhibiting the action of androgens
DE3590389T1 (de) * 1984-08-02 1986-08-28 Schering Corp., Kenilworth, N.J. Pharmazeutische Zusammensetzung für eine Kombinationstherapie hormon-abhängiger Cancer
US4659695A (en) * 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
DE3478398D1 (en) * 1984-10-10 1989-07-06 Ile De France Synergistic contraceptive mixture
GB8503940D0 (en) * 1985-02-15 1985-03-20 Erba Farmitalia 4-substituted androstendione derivatives
GB8505862D0 (en) * 1985-03-07 1985-04-11 Erba Farmitalia Steroidic 5alpha-reductase inhibitors
DE3607651A1 (de) * 1986-03-06 1987-09-10 Schering Ag Kombination von aromatasehemmer und testosteron-5(alpha)-reduktase-hemmer
IE60964B1 (en) * 1986-12-11 1994-09-07 Roussel Uclaf Zootechnical compositions containing a beta-adrenergic
US4888336A (en) * 1987-01-28 1989-12-19 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
DE3888378T2 (de) * 1987-04-03 1994-09-29 Merck & Co Inc Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia

Also Published As

Publication number Publication date
IE990530A1 (en) 2000-11-15
ATE269066T1 (de) 2004-07-15
CA2062973A1 (en) 1991-01-08
WO1991000731A1 (en) 1991-01-24
AU643445B2 (en) 1993-11-18
CA2062973C (en) 2003-09-23
JP2001354590A (ja) 2001-12-25
HUT60138A (en) 1992-08-28
EP0857487A3 (en) 1999-12-08
ES2222633T3 (es) 2005-02-01
EP0480950A1 (en) 1992-04-22
JPH04506798A (ja) 1992-11-26
US5817649A (en) 1998-10-06
MY106484A (en) 1995-05-30
EP0943328B1 (en) 2004-06-16
EP0857487A2 (en) 1998-08-12
JP3332377B2 (ja) 2002-10-07
ATE177949T1 (de) 1999-04-15
DE69033020T2 (de) 1999-08-05
IE902459A1 (en) 1991-02-13
DE69033020D1 (de) 1999-04-29
DE69034148D1 (de) 2004-07-22
EP0480950B1 (en) 1999-03-24
EP0943328A3 (en) 1999-12-08
DK0480950T3 (da) 1999-10-11
HU223662B1 (hu) 2004-11-29
NZ234414A (en) 1999-05-28
AU668434B2 (en) 1996-05-02
ES2133270T3 (es) 1999-09-16
IL94990A (en) 1997-01-10
IL94990A0 (en) 1991-06-10
AU5854590A (en) 1991-02-06
EP0943328A2 (en) 1999-09-22
ZA905312B (en) 1992-02-26
IE990531A1 (en) 2000-11-15
DE69034148T2 (de) 2005-06-30
AU5217493A (en) 1994-02-10
KR920703063A (ko) 1992-12-17
HU9200047D0 (en) 1992-06-29

Similar Documents

Publication Publication Date Title
DK0480950T3 (da) Kombinationsterapi til profylakse for og/eller behandling af godartet prostatahypertrofi
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
MX9702380A (es) Nuevas carboxamidas con actividad antifungica.
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
DK0891331T3 (da) N-(2-Oxoacetyl- eller sulfonyl)pyrrolidin/piperidin-2-carboxylsyrederivater med forbedret multi-lægemiddelresistensaktivitet
IL87885A (en) Pharmaceutical compositions having antiprogestational and anti-estrogenic activities for the treatment of hormone- dependent tumors
SE7903186L (sv) Cerebralverksamt medel
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
TR200101793T2 (tr) CCR5 modülatörleri olarak azabisikloalkanlar
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
ATE203019T1 (de) Neue (r)-5-carbamoyl-8-fluor-3-n,n- disubstituierte-amino-3,4-dihydro-2h-1- benzopyrane
IL101574A0 (en) Combination pharmaceutical compositions for the treatment of benign prostatic hyperplasia
SE9604348D0 (sv) Användning av hydroxyguanidiner
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
NO893142L (no) Fremgangsmaate for preservering av oftalmologiske opploesninger og sammensetninger for formaalet.
JPS5533497A (en) Silaasubstituted 1*44dihydropyridine derivative
NO20000519L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
NO20002408L (no) 5-HT1F antagonister
NO970573D0 (no) Ylidenforbindelser og deres fremstilling
IS5482A (is) Samsetning af virkum efnisþáttum sérstaklega af tetrahýdrópýridínum og asetýlkólín esterasa hindrandi miðlun til meðhöndlunar á elliglöpum á borð viðAlzheimers vitglöp
DE59101818D1 (de) Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung.
DK330687D0 (da) Forbindelser og farmaceutiske kompositioner, der er anvendelige som cardiotoniske midler
DK630088A (da) Azelastinembonat, fremgangsmaade til fremstilling deraf og farmaceutiske praeparater med indhold af denne forbindelse som aktivt middel
TR200000916T2 (tr) İkameli piperidin türevleri.
ATE82855T1 (de) 2',3'-dideoxypurinnucleosid/purinnucleosidphosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.